ArticleCritical care (London, England)2025
Discovery of a resistant cohort to acute kidney injury: insights from patients with septic shock.
Article in Critical care (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) is a significant complication among critically ill patients, particularly those with sepsis, yet no specific therapies exist. Progress in some diseases has been achieved by analyzing individuals who appear resistant. This study sought to develop a framework to investigate AKI resistance using clinical phenotyping and biomarkers and applied this framework to a large cohort of patients with septic shock.
methodsWe performed a retrospective analysis of patients enrolled in the Protocolized Care for Early Septic Shock (ProCESS) trial. We measured urinary tissue inhibitor of metalloproteinase-2 (TIMP-2), insulin-like growth factor binding protein 7 (IGFBP7), and kidney injury molecule 1 (KIM-1) 6 h after the start of resuscitation. AKI was defined first as high risk by [TIMP-2]•[IGFBP7] > 1.0 (ng/mL)²/1000 and either meeting Kidney Disease Improving Global Outcomes Criteria (KDIGO) criteria within 7 days after the start of resuscitation or having [KIM-1] > 2.0 ng/ml. AKI resistance was defined as the combination of (a) high-risk by [TIMP-2]•[IGFBP7] > 1.0 (ng/mL)²/1000 but without meeting (b) KDIGO AKI criteria nor (c) [KIM-1] > 2.0 ng/ml. We compared clinical characteristics and outcomes across three groups: AKI-resistant, AKI, and reduced risk, which was defined as [TIMP-2]•[IGFBP7] < 1.0 (ng/mL)²/1000.
resultsAmong 573 patients, 339 (59.2%) had reduced risk, 194 (33.9%) developed AKI, and 40 (7%) were AKI-resistant. Median (IQR) non-renal SOFA scores were lower for patients at reduced risk for AKI (5 [2-7]) than for those with AKI resistance (6 [4.5-8], P < 0.01) or AKI (6 [5-9], P < 0.01). Baseline characteristics did not differ between AKI-resistant and AKI-affected individuals. However, AKI-resistant patients experienced significantly lower 30-day mortality (10% vs. 32%; adjusted OR 0.26, 95% CI: 0.09-0.80, P = 0.02) and shorter ICU stays when compared to those with AKI.
conclusionDespite greater illness severity, AKI-resistant patients had similar mortality and length of stay as lower-risk patients but better outcomes than those with AKI. Studying these patients may reveal novel therapeutic targets for AKI prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.